18F-PSMA-1007 PET/CT与全身MRI及CT在前列腺癌淋巴结分期中的前瞻性比较
以多学科共识为参考标准,31例(39%)患者存在盆腔淋巴结转移;在乐观分析中,PET/CT、WBMRI和CT的患者水平灵敏度分别为0.87、0.37和0.26,特异性分别为0.98、0.98和1.00。结论认为18F-PSMA-1007 PET/CT的灵敏度显著高于WBMRI和CT,同时保持高特异性。
要点
- 18F-PSMA-1007 PET/CT患者水平灵敏度0.87,显著高于WBMRI的0.37和CT的0.26。
- PET/CT特异性0.98,与WBMRI(0.98)和CT(1.00)均保持高水平。
- 26%的患者仅PET/CT检出恶性淋巴结,而WBMRI和CT均为阴性。
核心结论
- 18F-PSMA-1007 PET/CT在原发前列腺癌淋巴结分期中的灵敏度显著高于全身MRI(含DWI)和CT,同时维持高特异性。
研究设计与样本
- 每种模态由两名读者独立盲法判读盆腔淋巴结为恶性、可疑或良性,采用乐观(可疑判为良性)和悲观(可疑判为恶性)分析。
- 参考标准基于多学科共识会议,结合可得组织病理学、临床和随访数据。
主要发现
- 31例(39%)患者存在盆腔淋巴结转移;乐观分析中,PET/CT、WBMRI和CT分别检出27/31(87%)、14/31(45%)和8/31(26%)例。
- 8/31(26%)患者仅PET/CT检出恶性淋巴结,而WBMRI和CT均报告阴性。
- 患者水平乐观分析:PET/CT灵敏度0.87(95%CI 0.71-0.95)、特异性0.98(95%CI 0.89-1.00);WBMRI灵敏度0.37(95%CI 0.22-0.55)、特异性0.98(95%CI 0.89-1.00);CT灵敏度0.26(95%CI 0.14-0.43)、特异性1.00(95%CI 0.93-1.00)。
关键数值与推荐
- 患者水平乐观分析灵敏度:18F-PSMA-1007 PET/CT 0.87(95%CI 0.71-0.95),WBMRI 0.37(95%CI 0.22-0.55),CT 0.26(95%CI 0.14-0.43)。
- 患者水平乐观分析特异性:18F-PSMA-1007 PET/CT 0.98(95%CI 0.89-1.00),WBMRI 0.98(95%CI 0.89-1.00),CT 1.00(95%CI 0.93-1.00)。
临床怎么用
- 对于新诊断的不利中危或高危前列腺癌患者,18F-PSMA-1007 PET/CT可作为盆腔淋巴结分期的高灵敏度影像手段。
- 在PET/CT上检出可疑淋巴结时,其高特异性有助于支持临床决策,但需结合多学科共识和后续验证。
局限性
- 参考标准基于多学科共识而非全部组织病理学验证,可能引入验证偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To prospectively compare 18F-prostate-specific membrane antigen (PSMA)-1007 positron emission tomography (PET)/CT, whole-body magnetic resonance imaging (WBMRI) including diffusion-weighted imaging (DWI) and standard computed tomography (CT), in primary nodal staging of prostate cancer (PCa). METHODS: Men with newly diagnosed unfavourable intermediate- or high-risk PCa prospectively underwent 18F-PSMA-1007 PET/CT, WBMRI with DWI and contrast-enhanced CT within a median of 8 days. Six readers (two for each modality) independently reported pelvic lymph nodes as malignant, equivocal or benign while blinded to the other imaging modalities. Sensitivity, specificity and accuracy were reported according to optimistic (equivocal lesions interpreted as benign) and pessimistic (equivocal lesions interpreted as malignant) analyses. The reference standard diagnosis was based on multidisciplinary consensus meetings where available histopathology, clinical and follow-up data were used. RESULTS: Seventy-nine patients completed all the imaging modalities, except for one case of interrupted WBMRI. Thirty-one (39%) patients had pelvic lymph node metastases, which were detected in 27/31 (87%), 14/31 (45%) and 8/31 (26%) patients by 18F-PSMA-1007 PET/CT, WBMRI with DWI and CT, respectively (optimistic analysis). In 8/31 (26%) patients, only 18F-PSMA-1007 PET/CT detected malignant lymph nodes, while the other two imaging modalities were reported as negative. At the patient level, sensitivity and specificity values for 18F-PSMA-1007 PET/CT, WBMRI with DWI and CT in optimistic analysis were 0.87 (95%CI 0.71-0.95) and 0.98 (95%CI 0.89-1.00), 0.37 (95%CI 0.22-0.55) and 0.98 (95%CI 0.89-1.00) and 0.26 (95%CI 0.14-0.43) and 1.00 (95%CI 0.93-1.00), respectively. CONCLUSION: 18F-PSMA-1007 PET/CT showed significantly greater sensitivity in nodal staging of primary PCa than did WBMRI with DWI or CT, while maintaining high specificity. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov ID: NCT03537391.
引用
- Malaspina S, Anttinen M, Taimen P, et al. Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 33715033. doi:10.1007/s00259-021-05296-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。